Sept 16 (Reuters) - Sanofi-Aventis SA:
* Receives complete response letter from the FDA for eplivanserin (Ciltyri(R))
submission
* Says currently reviewing the content of the complete response letter
* Says will contact the FDA in the coming days to request a meeting
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Receives complete response letter from the FDA for eplivanserin (Ciltyri(R))
submission
* Says currently reviewing the content of the complete response letter
* Says will contact the FDA in the coming days to request a meeting
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.